BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 22706919)

  • 1. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review.
    Backes Y; van der Sluijs KF; Mackie DP; Tacke F; Koch A; Tenhunen JJ; Schultz MJ
    Intensive Care Med; 2012 Sep; 38(9):1418-28. PubMed ID: 22706919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.
    Koch A; Voigt S; Kruschinski C; Sanson E; Dückers H; Horn A; Yagmur E; Zimmermann H; Trautwein C; Tacke F
    Crit Care; 2011; 15(1):R63. PubMed ID: 21324198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentraxin 3 as a prognostic biomarker in patients with systemic inflammation or infection.
    Liu S; Qu X; Liu F; Wang C
    Mediators Inflamm; 2014; 2014():421429. PubMed ID: 25530683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit.
    El-Mekkawy MS; Saleh NY; Sonbol AA
    Indian J Pediatr; 2016 Jul; 83(7):661-9. PubMed ID: 26960717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis.
    Ni W; Han Y; Zhao J; Cui J; Wang K; Wang R; Liu Y
    Sci Rep; 2016 Dec; 6():39481. PubMed ID: 27991579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients.
    Donadello K; Scolletta S; Taccone FS; Covajes C; Santonocito C; Cortes DO; Grazulyte D; Gottin L; Vincent JL
    J Crit Care; 2014 Feb; 29(1):144-9. PubMed ID: 24120089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study.
    Uusitalo-Seppälä R; Huttunen R; Tarkka M; Aittoniemi J; Koskinen P; Leino A; Vahlberg T; Rintala EM
    J Intern Med; 2012 Sep; 272(3):247-56. PubMed ID: 22755554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study.
    Jalkanen V; Vaahersalo J; Pettilä V; Kurola J; Varpula T; Tiainen M; Huhtala H; Alaspää A; Hovilehto S; Kiviniemi O; Kuitunen A; Tenhunen J;
    Resuscitation; 2014 Nov; 85(11):1562-7. PubMed ID: 25193800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of soluble urokinase plasminogen activator receptor (suPAR) as a marker of sepsis in the emergency department setting. A current review.
    Velissaris D; Pierrakos C; Karamouzos V; Pantzaris ND; Gogos C
    Acta Clin Belg; 2021 Feb; 76(1):79-84. PubMed ID: 31434557
    [No Abstract]   [Full Text] [Related]  

  • 10. A Comparative Study of the Diagnostic and Prognostic Utility of Soluble Urokinase-type Plasminogen Activator Receptor and Procalcitonin in Patients with Sepsis and Systemic Inflammation Response Syndrome.
    Sharma A; Ray S; Mamidipalli R; Kakar A; Chugh P; Jain R; Ghalaut MS; Choudhury S
    Indian J Crit Care Med; 2020 Apr; 24(4):245-251. PubMed ID: 32565634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome.
    Hoenigl M; Raggam RB; Wagner J; Valentin T; Leitner E; Seeber K; Zollner-Schwetz I; Krammer W; Prüller F; Grisold AJ; Krause R
    Clin Biochem; 2013 Feb; 46(3):225-9. PubMed ID: 23159293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic value of soluble urokinase plasminogen activator receptor (suPAR) compared to C-reactive protein (CRP) and procalcitonin (PCT) in children with systemic inflammatory response syndrome (SIRS).
    Şirinoğlu M; Soysal A; Karaaslan A; Kepenekli Kadayifci E; Yalındağ-Öztürk N; Cinel İ; Yaman A; Haklar G; Şirikci Ö; Turan S; Altınkanat Gelmez G; Söyletir G; Bakır M
    J Infect Chemother; 2017 Jan; 23(1):17-22. PubMed ID: 27771157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. suPAR as a prognostic biomarker in sepsis.
    Donadello K; Scolletta S; Covajes C; Vincent JL
    BMC Med; 2012 Jan; 10():2. PubMed ID: 22221662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome.
    Raggam RB; Wagner J; Prüller F; Grisold A; Leitner E; Zollner-Schwetz I; Valentin T; Krause R; Hoenigl M
    J Intern Med; 2014 Dec; 276(6):651-8. PubMed ID: 24645798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of decoy receptor 3 combined with procalcitonin and soluble urokinase-type plasminogen activator receptor for sepsis.
    Zhao JJ; Lou XL; Chen HW; Zhu FT; Hou YQ
    Cell Mol Biol Lett; 2018; 23():22. PubMed ID: 29760745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Diagnostic and Prognostic Value of suPAR in Patients with Sepsis: A Systematic Review and Meta-Analysis.
    Huang Q; Xiong H; Yan P; Shuai T; Liu J; Zhu L; Lu J; Yang K; Liu J
    Shock; 2020 Apr; 53(4):416-425. PubMed ID: 31490358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit.
    Reisinger AC; Niedrist T; Posch F; Hatzl S; Hackl G; Prattes J; Schilcher G; Meißl AM; Raggam RB; Herrmann M; Eller P
    Sci Rep; 2021 Sep; 11(1):17476. PubMed ID: 34471146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality.
    Zimmermann HW; Reuken PA; Koch A; Bartneck M; Adams DH; Trautwein C; Stallmach A; Tacke F; Bruns T
    J Intern Med; 2013 Jul; 274(1):86-100. PubMed ID: 23432143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis.
    Zeng M; Chang M; Zheng H; Li B; Chen Y; He W; Huang C
    Am J Emerg Med; 2016 Mar; 34(3):375-80. PubMed ID: 26615223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor.
    Giamarellos-Bourboulis EJ; Norrby-Teglund A; Mylona V; Savva A; Tsangaris I; Dimopoulou I; Mouktaroudi M; Raftogiannis M; Georgitsi M; Linnér A; Adamis G; Antonopoulou A; Apostolidou E; Chrisofos M; Katsenos C; Koutelidakis I; Kotzampassi K; Koratzanis G; Koupetori M; Kritselis I; Lymberopoulou K; Mandragos K; Marioli A; Sundén-Cullberg J; Mega A; Prekates A; Routsi C; Gogos C; Treutiger CJ; Armaganidis A; Dimopoulos G
    Crit Care; 2012 Aug; 16(4):R149. PubMed ID: 22873681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.